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Ganstigmine (CHF2819) in Phase II: It is a novel AChE inhibitor derived from genserine, for which animal models suggest significant neuroprotection independent from its cholinergic activity. Chiesi Farmaceutici had been testing ganstigmine hydrochloride in Phase II for the treatment of AD; however, the company discontinued development of the drug candidate in order to focus resources on other therapeutic areas [http:// www.centerwatch.com, http://integrity.prous.com/]. IP-751 (Ajulemic acid, CT-3) in Phase II: It is a synthetic analogue of the THC metabolite, THC-11-oic acid developed by Atlantic Technology Ventures, U.S.A. and is currently at Indevus in Phase II clinical trials for the treatment of neuropathic pain. It is also undergoing clinical trials for treatment of tremor and spasticity in multiple sclerosis. IP-751 appears to inhibit COX-2 and other inflammatory cytokines, particularly interleukin-1b, TNF-a and also the Peroxisomes Proliferating Activated Receptor-g (PPAR-g) and is partial cannabinoid (CB) receptor agonist [11, 36] ; [http://integrity.prous.com/]. LLL-2011 (Amigra) in Phase III: It is a botanical drug being developed by Lupin as a nasal spray for prophylaxis of migraine. Lupin has received regulatory approval in India to conduct clinical trials in 10 centres. In Phase II clinical trial it was found to be safe and well tolerated with good efficacy data [37]; [http://www.lupinworld.com/]. Lobeline in Phase I: It is a pyridine alkaloid isolated from Lobelia inflata (Campanulaceae), which has been used for centuries as an emetic and respiratory stimulant and, more recently, as a smoking cessation agent. Yaupon Therapeutics and NIH are evaluating Lobeline for methamphetamine addiction. Preclinical studies have suggested that lobeline has utility in helping to treat attention deficit hyperactivity disorder (ADHD) [11] ; [http://www.yaupontherapeutics.com/]. M6G in Phase III: It is morphine 6-glucuronide a metabolite of morphine, the naturally occurring alkaloid in the opium poppy (Papaver somniferum). M6G is being developed by CeNeS Pharmaceuticals plc for post-operative pain following surgical procedure and has shown promising results comparable to morphine. It has superior side effect profile in terms of reduced liability to induce nausea, vomiting and respiratory depression. It has higher efficacy and low affinity on m-opioid receptor than morphine. The U.S. FDA has approved the IND application for the clinical development of M6G. CeNeS is currently completing the protocol design of the first U.S. Phase III trial [38] 35963, a muscarinic M1 agonist. After oral administration, RU 47213 seems superior to arecoline in terms of potency, central selectivity and duration of action, and is also active in animal models of cognition, without eliciting significant cholinergic side effects [39] . THC-CBD (Dronabinol/cannabidiol, GW-1000-02, Sativex 1 ) in Phase III: It is a cannabis (Cannabis sativa)-based pharmaceutical product containing delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio and is being developed by GW Pharmaceuticals. It has been approved as adjunctive treatment for neuropathic pain and cancer pain with multiple sclerosis (MS) in U.K. and Canada. It is being investigated for the management of other MS symptoms, such as spasticity. They act on CB receptors that are involved in the control of spasticity where there is neurological damage. The most common adverse events (AEs) reported in trials were dizziness, sleepiness, fatigue, feeling of intoxication and a bad taste [http://www.gwpharm.-com/, http://www.clinicaltrial.gov]. ZT-1 (DEBIO-9902) in Phase II: It is a pro-drug of huperzine isolated from the club moss, Huperzia serrata (Lycopodiaceae). ZT-1 was originally synthesized by Zhu and co-workers at Shanghai Institute of Material Medica. It is being evaluated by Debiopharm for the treatment of AD. The dual mode of action of ZT-1, as a N-methyl-D-aspartate receptor antagonist and an AChE inhibitor, positions it as a third generation antiAlzheimer's product by improving the general condition and cognitive functions of affected patients as well as having the potential of being a neuroprotectant [http://www.debiopharm. com/; [11] .
Cardiovascular and metabolic disease applications
Cardiovascular and metabolic diseases have been major causes of death throughout the world and are an ever increasing disease area because of the modern life style. According to the WHO cardiovascular diseases are the leading causes of death, responsible for 30% of all deaths or 17.5 million deaths in 2005 [25] . According to the International Diabetes Federation, 41 million people in India have diabetes, and this is expected to increase to 75-100 million people by 2025. Thus, there is a need for new drugs in these categories in both the developed and developing worlds. Plant-based drugs have been a useful source of active compounds for these indications, including cardiac drugs like digoxin, sennosides, forskolin and aglucosidase inhibitors such as miglitol, for type 2 diabetes mellitus. Those drugs currently in clinical trials for these indications are reported below.
P-57 (P-57AS3) in Phase II: This is a functional food product candidate based on an extract of the succulent plant Hoodia gordonii (Asclepiadaceae), which has been traditionally eaten by Kung people of Kalahari desert to avoid feelings of hunger and thirst during hunting. P-57, a steroid glycoside, and related compounds were isolated from Hoodia gordonii by the South African Council for scientific and Industrial Research (CSIR). P-57 contains a novel satiety stimulator that reduces calorie intake in overweight subjects and, at present, is being developed by Phytopharm and Unilever for the oral treatment of obesity. 
Inflammatory and related disease applications
Plant-based drugs and many herbal preparations alter immune function and have an amazing array of immunomodulatory effects attributed to them [40] . The salicyclic acid derivative, aspirin, has been a cornerstone for the treatment of inflammation-associated diseases, and many plant-based preparations have also been reported for their activity against immunological conditions [41] . 
Oncological disease applications
Cancer is a complex disease that involves uncontrolled multiplication and spread (metastasis) of abnormal form of body's own cells. As per WHO 13% of world deaths, that is, about 7.6 million deaths accounted in 2005 are because of cancer, and this percentage is expected to increase in coming years [25] . Plantderived compounds have played an important role in treatment of cancers, and some of the most promising and better drugs have come up from plant sources like Taxol 1 [43] , Camptothecin [44] , Combrestatin [45] , Epipodophyllotoxin [46] and Vinca alkaloids (vinblastine, vincristine [47] . These drugs have also been the major source of new drug candidates for the treatment of cancers. Apart from this many other plant-derived compounds that are in clinical trials for cancers are tabulated in Tables 2  and 3 .
Conclusion and future perspectives
The resurgence of plant-based drugs, as evident by the number of drugs in clinical trials, mainly for the treatment of cancer, immunological and CNS related diseases, is certainly exciting. There are many new plant-based drug candidates in active preclinical trials like Prostratin, CAPSOROLS and CCS. Inputs from traditional medical knowledge and using modern techniques to speed up the plant-based drug discovery have now made us to think beyond the only 10-15% of plant diversity that have been explored for their pharmaceutical purpose so far. Plants, the best combinatorial chemists, still wait for us to discover the hitherto hidden secrets of their healing properties to unburden mankind from dreaded diseases. Over 60 compounds are in the pipeline, as anticancer drugs alone, from plant sources. This is expected to remain an interesting disease area in the future as well. We must equip ourselves to screen a sizeable number of plants from our .27 million plant species, which can only be achieved by the concerted efforts exemplified by the NCI in recent years.
